Infliximab for psoriasis

Research output: Contribution to journalReview articlepeer-review

108 Scopus citations

Abstract

This review summarizes the use of inflximab in psoriasis and other immune-mediated inflammatory disorders (IMIDs). The magnitude and speed of the response to infliximab monotherapy of moderate to severe psoriasis vulgaris is substantial, being similar to those achieved with cyclosporin. In contrast with cyclosporin, clinical improvement after the initial 3 intravenous influsions of infliximab is maintained for as long as 6 months in approximately half the patients with the absence of any additional treatment. Additionally, infliximab monotherapy normalizes keratinocyte proliferation and differentiation and markedly decreases epidermal inflammation. These results provide a convincing argument for the role of TNF-α in the pathogenesis of psoriasis and for the clinical development of infliximab for the treatment of psoriasis.

Original languageEnglish
Pages (from-to)112-117
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume49
Issue number2 A
DOIs
StatePublished - 1 Aug 2003
Externally publishedYes

Fingerprint

Dive into the research topics of 'Infliximab for psoriasis'. Together they form a unique fingerprint.

Cite this